Brasic J R, Barnett J Y, Kaplan D, Sheitman B B, Aisemberg P, Lafargue R T, Kowalik S, Clark A, Tsaltas M O, Young J G
Department of Psychiatry, Bellevue Hospital Center, New York, NY.
Neurology. 1994 Jul;44(7):1309-12. doi: 10.1212/wnl.44.7.1309.
In an open, nonblind clinical trial, clomipramine reduced adventitious movements and compulsions in five previously medicated prepubertal boys with autistic disorder and severe mental retardation. Poorly adapted rating scales, interrater variability, subject heterogeneity, different treatment histories, and environmental stresses confounded the assessment of treatment effects.
在一项开放、非盲法的临床试验中，氯米帕明减少了5名之前接受过药物治疗的患有自闭症谱系障碍和严重智力障碍的青春期前男孩的不自主运动和强迫行为。评定量表适用性差、评定者间的变异性、受试者的异质性、不同的治疗史以及环境压力混淆了治疗效果的评估。
